PropertyValue
?:abstract
  • Dysregulated IL-1β and IL-6 responses have been implicated in the pathogenesis of severe Coronavirus Disease 2019 (COVID-19). Innovative approaches for evaluating the biological activity of these cytokines in vivo are urgently needed to complement clinical trials of therapeutic targeting of IL-1β and IL-6 in COVID-19. We show that the expression of IL-1β or IL-6 inducible transcriptional signatures (modules) reflects the bioactivity of these cytokines in immunopathology modelled by juvenile idiopathic arthritis (JIA) and rheumatoid arthritis. In COVID-19, elevated expression of IL-1β and IL-6 response modules, but not the cytokine transcripts themselves, is a feature of infection in the nasopharynx and blood, but is not associated with severity of COVID-19 disease, length of stay or mortality. We propose that IL-1β and IL-6 transcriptional response modules provide a dynamic readout of functional cytokine activity in vivo, aiding quantification of the biological effects of immunomodulatory therapies in COVID-19.
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.isci.2020.101896
?:doi
?:journal
  • iScience
?:license
  • els-covid
?:pdf_json_files
  • document_parses/pdf_json/1f92a555ebf20bb24bc6e8bcd4ebc000a716f1cb.json; document_parses/pdf_json/97ba6897731a1b412608646d0c7ad2a1eda07188.json
?:pmcid
?:pmid
?:pmid
  • 33319166.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Transcriptional response modules characterise IL-1β and IL-6 activity in COVID-19
?:type
?:year
  • 2020-12-07

Metadata

Anon_0  
expand all